Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

27 Oct 2022

Abstract excerpt

Abstract The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36302754
DOI: 10.1038/s41467-022-33746-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaPMID 36302754Read ↗

Decoding Neoantigen-encoding Tumor-Specific Transcripts Unveils a Shared Target Reservoir for Immunotherapy in Hepatocellular CarcinomaSemantic proximity Read ↗

Detection of a Recurrent <i>DNAJB1-PRKACA</i> Chimeric Transcript in Fibrolamellar Hepatocellular CarcinomaSemantic proximity Read ↗

Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACASemantic proximity Read ↗

Specific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNASemantic proximity Read ↗

Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar CarcinomaSemantic proximity Read ↗

Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinomaSemantic proximity Read ↗

Discovery and validation of non-canonical antigens for Hepatocellular Carcinoma immunotherapySemantic proximity Read ↗

DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.Semantic proximity Read ↗

Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.Semantic proximity Read ↗

Non-canonical ORFs are an important source of tumor-specific antigens in a liver cancer meta-cohortSemantic proximity Read ↗

Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockadeSemantic proximity Read ↗

Pancreatic cancer–restricted cryptic antigens are targets for T cell recognitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.